Heron Therapeutics, Inc. (HRTX) vs INmune Bio, Inc. (INMB)

Heron Therapeutics, Inc. and INmune Bio, Inc. are both Biotechnology companies. Heron Therapeutics, Inc. and INmune Bio, Inc. are of similar size ($57.0M and $55.5M). Heron Therapeutics, Inc. grew revenue faster over the last twelve months: 0.99% against −51.6%. INmune Bio, Inc. has the higher net margin (0.00% vs −22.5%) and the lower return on invested capital (−646.9% vs −6.35%). Across the 18 metrics below, INmune Bio, Inc. leads on 10 and Heron Therapeutics, Inc. on 8.

Valuation

Metric HRTX INMB Biotechnology median
P/E n/m n/m 7.88
P/S 0.38 401.77 11.47
P/B 9.75 2.66 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 1.04 301.47 10.73
Earnings yield (63.33%) (33.00%) (28.84%)
Free cash flow yield (21.17%) (30.30%) (23.03%)

Profitability

Metric HRTX INMB Biotechnology median
Gross margin 70.07% 100.00% 65.16%
Operating margin (7.19%) 0.00% 0.00%
Net margin (22.52%) 0.00% 0.00%
Free cash flow margin (8.00%) 0.00% 0.00%
Return on equity 318.21% (74.82%) (57.72%)
Return on assets (14.06%) (57.08%) (49.22%)
Return on invested capital (6.35%) (646.94%) 0.00%

Growth

Metric HRTX INMB Biotechnology median
Revenue growth (TTM) 0.99% (51.61%) 5.64%
EPS growth (last fiscal year) (33.33%) 11.85% —
Revenue growth, 5-year CAGR 11.81% 35.37% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric HRTX INMB Biotechnology median
Debt to equity 20.65 0.00 0.00
Current ratio 2.49 4.04 4.73
Net debt to EBITDA (643.88) 0.52 0.96

Dividend

Metric HRTX INMB Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric HRTX INMB Biotechnology median
Market cap 56.96m 55.51m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack